Barn og HIV/AIDS – forebygging, oppfølging og behandling
- 1.
Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morbid Mortal Wkly Rep 1998; 47 (RR – 4): 1 – 43.
- 2.
Centers for Disease Control and Prevention. Public Health Service Task Force Recommendations for the use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR Morbid Mortal Wkly Rep 1998; 47 (RR – 2): 1 – 29.
- 3.
Recommendations for the management of HIV-infected women and their infants – a European consensus. Prenat Neonat Med 1999; 4: 3 – 17.
- 4.
UNAIDS. Report on the Global HIV/AIDS Epidemic, December, 1998. Genève: UNAIDS, 1998.
- 5.
AIDS og HIV-infeksjon meldt til Folkehelsa. MSIS-rapport 1999; 27: 14.
- 6.
Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double blind controlled trial of immediate and deferred zidovudine in asymptomatic HIV infection. Lancet 1994; 343: 871 – 81.
- 7.
Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283 – 91.
- 8.
Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339: 1261 – 8.
- 9.
Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial. JAMA 1998; 279: 930 – 7.
- 10.
Pediatric European Network for Treatment of AIDS. PENTA News 1999; 2: 4.
- 11.
Mueller BU, Nelson RP, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM et al. A phase I/II study of the protease inhibitor retonavir in children with human immunodeficiency virus infection. Pediatrics 1998; 101: 335 – 43.
- 12.
Hannet I, Erkeller-Yuksel F, Lydyard P, Deneys V, DeBruyere M. Developmental and maturational changes in human blood lymphocyte subpopulations. Immunol Today 1992; 13: 215 – 8.
- 13.
Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA et al. Disease progression in HIV – infected infants and children: predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count. JAMA 1998; 279: 756 – 61.
- 14.
Mofenson L, Korelitz J, Meyer WA, Bethel J, Rich K, Pahwa S et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long term mortality risk in HIV-1 infected children. J Infect Dis 1997; 175, 1029 – 38.
- 15.
Ziegler JB, Cooper DA, Gold J, Johnston R. Postnatal transmission of AIDS-associated retrovirus. Lancet 1985; 1: 896 – 8.
- 16.
Pediatric AIDS Clinical Trials Group Protocol, 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173 – 80.
- 17.
The International Perinatal HIV Group. The Mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. N Engl J Med 1999; 340: 977 – 87.
- 18.
Centers for Disease Control. 1994 Revised human immunodeficiency virus pediatric classification system: clinical categories. MMWR Morbid Mortal Wkly Rep 1994; 43: 1 – 10.
- 19.
Nøkleby H, red. Veiledning om vaksinasjon. Oslo: Statens institutt for folkehelse, 1998: 30.
- 20.
Sharland M, Gibb D, Tudor-Williams G, Walters S, Novelli V. Paediatric HIV infection. Arch Dis Child 1997; 76: 293 – 7.
- 21.
European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet 1992; 339: 1007 – 12.
- 22.
Smith D. Compliance and toxicity concerns with antiretroviral therapy. J HIV Therapy 1998; 3: 55 – 7.